Table 1.
Model parameters
|
Name |
Description |
Deterministic value |
Probabilistic components |
Source |
|||||
|---|---|---|---|---|---|---|---|---|---|
| |
|
|
Distribution |
Range |
|
Gamma |
Alpha1 |
Alpha 2 |
|
| Min | Max | ||||||||
| cDR |
Cost discount rate |
0.035 |
Fixed |
|
|
|
|
|
Pharmaco economic guidelines (NICE) |
| oDR |
Outcome discount rate |
0.035 |
Fixed |
|
|
|
|
|
Pharmaco economic guidelines (NICE) |
| cArgus II |
Costs of device + implantation |
90800 |
BETA Pert |
68100 |
113500 |
8 |
5 |
5 |
Second Sight |
| cRP |
Annual health care costs incurred on RP patients |
11789 |
BETA Pert |
8841 |
14736 |
8 |
5 |
5 |
Frick et al. [14] |
| cVA+ |
Annual health care costs incurred on RP patients with VA+ |
9431 |
BETA Pert |
7073 |
11789 |
8 |
5 |
5 |
Frick et al. [14] + assumption |
| cVA++ |
Annual health care costs incurred on RP patients with VA++ |
8252 |
BETA Pert |
6189 |
10315 |
8 |
5 |
5 |
Frick et al. [14]+ assumption |
| cVA+++ |
Annual health care costs incurred on RP patients with VA+++ |
7073 |
BETA Pert |
5305 |
8841 |
8 |
5 |
5 |
Frick et al. [14] + assumption |
| cSAE |
Cost of management of Serious Adverse Event |
1000 |
BETA Pert |
750 |
1250 |
8 |
5 |
5 |
Expert opinion |
| cExplant |
Cost of Explantation |
2000 |
BETA Pert |
1500 |
2500 |
8 |
5 |
5 |
Humayun et al. [9]/Second sight |
| cOthers |
Annual other costs for Argus II patients (e.g. Upgrades etc.) |
300 |
BETA Pert |
225 |
375 |
8 |
5 |
5 |
Humayun et al. [9]/Second sight |
| pVA+ |
Argus II patient’s annual probability of getting VA+ |
0.74 |
BETA Pert |
0.554 |
0.924 |
8 |
5 |
5 |
Humayun et al. [9]/Second Sight |
| pVA++ |
Argus II patient’s annual probability of getting VA++ |
0.21 |
BETA Pert |
0.154 |
0.257 |
8 |
5 |
5 |
Humayun et al. [9]/Second sight |
| pVA+++ |
Argus II patient’s annual probability of getting VA++ |
0.04 |
BETA Pert |
0.029 |
0.049 |
8 |
5 |
5 |
Humayun et al. [9]/Second sight |
| pSAE |
Probability of Serious Adverse Event in Argus II patients in first year |
0.3 |
BETA Pert |
0.225 |
0.375 |
8 |
5 |
5 |
Humayun et al. [9]/Second Sight |
| pExplant |
Argus II patient’s annual probability of device explantation |
0.02 |
BETA Pert |
0.013 |
0.021 |
8 |
5 |
5 |
Humayun et al. [9]/Second Sight |
| uRP |
Utility value in RP patients |
0.26 |
BETA Pert |
0.195 |
0.325 |
8 |
5 |
5 |
Brown et al. [18] |
| uVA+ |
Utility value in RP patients with VA+ |
0.35 |
BETA Pert |
0.263 |
0.438 |
8 |
5 |
5 |
Brown et al. [18] |
| uVA++ |
Utility value in RP patients with VA++ |
0.52 |
BETA Pert |
0.39 |
0.65 |
8 |
5 |
5 |
Brown et al. [18] |
| uVA+++ |
Utility value in RP patients with VA+++ |
0.54 |
BETA Pert |
0.405 |
0.675 |
8 |
5 |
5 |
Brown et al. [18] |
| uSAE |
(dis) utility value in patients with Serious Adverse Events |
0.16 |
BETA Pert |
0.12 |
0.2 |
8 |
5 |
5 |
Schiffman et al. [19] |
| uExplant | Utility value in patients post Argus II explantation | 0.26 | BETA Pert | 0.195 | 0.325 | 8 | 5 | 5 | Assumption |